Skip Navigation
Search Menu
Find an Expert


John M. Abraham, Ph.D.

Photo of Dr. John M. Abraham, Ph.D.

Assistant Professor of Medicine

Contact for Research Inquiries

1503 E. Jefferson Street
Room 103
Baltimore, MD 21205 map
Phone: 410-502-6057
Fax: 410-502-1329


For the last several years, Dr. Abraham has been investigating and developing potential new small molecule cancer therapeutics. Libraries of small peptides were prepared using recombinant means for screening assays which included binding to and the transfer of radioactivity to various human cancer cell lines in culture. Certain decapeptides with demonstrated binding and transfer potential were chemically synthesized and further studied. The majority of his research work over the last five years has centered on investigating and assaying the inhibition of growth of human-derived xenografted tumors in immunocompromised mice (nude mice and NOD/SCID). The discovery of a method to strongly inhibit xenografted tumor growth has recently been published, and the JHU Technology Transfer Office submitted a provisional patent application based on this work to the US Patent and Trademark Office in June 2013. more


  • Assistant Professor of Medicine

Research & Publications

Research Summary

Previously, the majority of my experimental work utilized siRNA knockdown techniques and microarray technology to identify and characterize downstream genetic targets of regulator genes. Recently, I have been involved in identifying novel decapeptides that, when labeled with 32P radioisotope, can transfer this tumor-ablating agent to colon and esophageal adenocarcinoma cells.

Selected Publications

1. Blount PL, Galipeau PC, Sanchez CA, Neshat K, Levine DS, Yin J, Suzuki H, Abraham JM, Meltzer SJ, Reid BJ. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res. 1994; 54:2292-2295

2. Meltzer SJ, Yin J, Manin B, Rhyu M-G, Cottrell J, Hudson E, Redd JL, Krasna MJ, Abraham JM, Reid BJ. Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas. Cancer Res. 1994; 54:3379-3382.

3. Suzuki H, Harpaz N, Tarmin Y, Yin J, Jiang H-Y, Bell JD, Hontanosas M, Groisman GM, Abraham JM, Meltzer SJ. Microsatellite instability in ulcerative colitis-associated colorectal dysplasias and cancers. Cancer Res. 1994; 54:4841-4844.

4. Harpaz N, Peck AL, Yin J, Fiel I, Hontanosas M, Tong TR, Laurin JN, Abraham JM, Greenwald BD, Meltzer SJ. p53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma. Human Pathol. 1994; 25:1069-1074.

5. Zhou X, Tarmin L, Yin J, Jiang H-Y, Suzuki H, Rhyu M-G, Abraham JM, Meltzer SJ. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 1994; 9:3737-3741.

6. Tarmin L, Yin J, Zhou X, Suzuki H, Jiang H-Y, Abraham JM, Krasna MJ, Cottrell J, Meltzer SJ. Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus. Cancer Res. 1994; 54:6094-6096.

7. Balcer-Kubiczek EK, Yin J, Lin K, Harrison GH, Abraham JM, Meltzer SJ. p53 mutational status and survival of human breast cancer MCF7 cell variants after exposure to X-rays or fission neutrons. Radiation Res. 1995; 142:256-262.

8. Zhou X, Suzuki H, Shimada Y, Imamura M, Yin J, Jiang H-Y, Tarmin L, Abraham JM, Meltzer SJ. Genomic DNA and messenger RNA expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines. Genes, Chromosomes & Cancer 1995; 13:285-290.

9. Suzuki H, Zhou X, Yin J, Lei J, Jiang H-Y, Suzuki Y, Abraham JM, Chan T, Hannon GJ, Mergner WJ, Abraham JM, Meltzer SJ. Intragenic mutations of p15 and p16 in primary human esophageal cancers. Human Molec. Genet. 1995; 4:1883-1888.

10. Berg PE, Liu J, Yin J, Rhyu M-G, Frantz CN, Meltzer SJ. Microsatellite instability is infrequent in neuroblastoma. Cancer Epidemiology, Biomarkers & Prevention 1995; 4:907-909.

11. Abraham JM, Wang S, Suzuki H, Jiang H-Y, Rosenblum-Vos LS, Yin J, Meltzer SJ. Esophagin cDNA cloning and characterization: a tissue-specific member of the small proline-rich protein family that is not expressed in esophageal tumors. Cell Growth & Different. 1996; 7:855-860.

12. Zhou X, Suzuki H, Lei J, Cole K, Yin J, Suzuki Y, Abraham JM, Shimada Y, Imamura T, Chan JT, Hannon GJ, Meltzer SJ. Growth suppression of esophageal cancer cells by p16INK4 and p15INK4B in vitro. Cancer J. Sci. Am. 1996; 2:221-224.

13. Souza RF, Appel R, Yin J, Wang S, Smolinski KN, Abraham JM, Zou T-T, Shi Y-Q, Lei J, Cottrell J, Cymes K, Biden K, Simms L, Leggett B, Lynch PM, Frazier M, Powell SM, Harpaz N, Sugimura H, Young J, Meltzer SJ. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumors. Nature Genet. 1996; 14:255-257.

14. Lei J, Zou T-T, Shi Y-Q, Smolinski KN, Yin J, Souza RF, Appel R, Wang S, Cymes K, Chan O, Harpaz N, Abraham JM, Meltzer SJ. Infrequent DPC4 gene mutation in esophageal cancer, gastric cancer, and ulcerative colitis-associated neoplasms. Oncogene 1996; 13:2459-2462.

15. Balcer-Kubiczek EK, Harrison GH, Zhang X-F, Shi Z-M, Abraham JM, McCready WA, Ampey III LL, Meltzer SJ, Jacobs MC, Davis CC. Rodent cell transformation and immediate early gene expression following 60-Hz magnetic field exposure. Envir. Health Perspect. 1996; 104:1188-1198.

16. Souza RF, Lei J, Yin J, Appel R, Zou T-T, Zhou X, Wang S, Rhyu M-G, Cymes K, Chan O, Park W-S, Krasna MJ, Greenwald BD, Cottrell J, Abraham JM, Harpaz N, Meltzer SJ. A transforming growth factor-?1 receptor type II mutation occurs in ulcerative colitis-associated and sporadic colorectal neoplasms. Gastroenterol. 1997; 112:40-45.

17. Balcer-Kubiczek EK, Meltzer SJ, Han L-H, Zhang X-F, Zhong M-S, Harrison GH, Qin JT, Abraham JM. Csa-19, a radiation-responsive human gene, identified by an unbiased two-gel cDNA library screening method. Oncogene 1997; 14:3051-3058.

18. Souza RF, Yin J, Smolinski KN, Zou T-T, Wang S, Shi Y-Q, Rhyu M-G, Cottrell J, Abraham JM, Biden K, Simms L, Leggett B, Bova GS, Frank T, Powell SM, Sugimura H, Young J, Harpaz N, Shimizu K, Matsubara N, Meltzer SJ. Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors. Cancer Res. 1997; 57:2350-53.

19. Zou T-T, Lei J, Shi Y-Q, Yin J, Wang S, Souza RF, Smolinski KN, Greenwald BD, Abraham JM, Harpaz N, Meltzer SJ. FHIT gene alterations in ulcerative colitis (UC) and esophageal cancer. Oncogene 1997; 15:101-105.

20. Wang S, Souza RF, Kong D, Yin J, Smolinski KN, Zou T-T, Young J, Flanders K, Sugimura H, Abraham JM, Meltzer SJ. Deficient transforming growth factor-?1 activation and excessive insulin-like growth factor II expression in IGFII receptor-mutant tumors. Cancer Res. 1997; 57:2543-2546.

21. Kong D, Suzuki A, Zou T-T, Sakurada A, Kemp LW, Wakatsuki S, Yokoyama T, Yamakawa H, Furukawa T, Sato M, Ohuchi N, Sato S, Yin J, Wang S, Abraham JM, Souza RF, Smolinski KN, Meltzer SJ, Horii A. PTEN1 is frequently mutated in primary endometrial carcinomas. Nature Genet. 1997; 17:143-144.

22. Yin J, Kong D, Wang S, Zou T-T, Souza RF, Smolinski KN, Lynch PM, Frazier M, Hamilton SR, Sugimura H, Powell SM, Young J, Abraham JM, Meltzer SJ. Mutation of the hMSH3 and hMSH6 mismatch repair genes in genetically unstable human colorectal and gastric carcinomas. Human Mutation 1997; 10:474-478.

23. Zou T, Fleisher AS, Kong D, Yin J, Souza RF, Wang S, Smolinski KN, Abraham JM, Meltzer SJ. Sequence alterations of IGFBP-3 in neoplastic and normal gastrointestinal tissues. Cancer Res. 1998; 58:4802-4804.

24. Balcer-Kubiczek EK, Zhang XF, Han LH, Harrison GH, Davis CC, Zhou XJ, Ioffe V, McCready WA, Abraham JM, Meltzer SJ. BIGEL analysis of gene expression in HL60 cells exposed to X rays or 60 Hz magnetic fields. Radiation Res. 1998; 150:663-672.

25. Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin Y, Zou T-T, Abraham JM, Kong D, Smolinski KN, Shi Y-Q, Rhyu M-G, Powell SM, James SP, Wilson KT, Herman JG, Meltzer SJ. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res. 1999; 59:1090-1095.

26. Yin J, Harpaz N, Souza RF, Zou T, Kong D, Wang S, Leytin AL, Medalie NS, Smolinski KN, Abraham JM, Fleisher AS, Meltzer SJ. Low prevalence of the APC I1307K sequence in patients with inflammatory bowel disease. Oncogene 1999; 18:3902-3904.

27. Souza RF, Wang S, Thakar M, Grubb J, Smolinski KN, Yin J, Zou T-T, Kong D, Gable CA, Sly WS, Abraham JM, Toretsky JA, Meltzer SJ. Expression of the wild-type insulin-like growth factor II receptor gene suppresses growth and causes death in colorectal carcinoma cells. Oncogene 1999; 18:4063-4068.

28. Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM, Kong D, Smolinski KN, Wilson KT, James SP, Silverberg SG, Nishizuka S, Motoyama T, Meltzer SJ. E-cadherin gene promoter hypermethylation in primary gastric carcinomas. J. Natl. Cancer Inst. 2000; 92:569-573.

29. Fleisher AS, Esteller M, Leytin A, Harpaz N, Rashid A, Xu Y, Liang J, Stine OC, Yin J, Zou T-T, Abraham JM, Kong D, Wilson KT, James SP, Herman JG, Meltzer SJ. Microsatellite instability in IBD-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res. 2000; 60:4864-4868.

30. Kawakami, K., Brabender, J., Lord, R.V., Groshen, S., Greenwald, B.D., Krasna, M.J., Yin, J., Fleisher, A.S., Abraham, J.M., Beer, D.G., Sidransky, D., Huss, H.T., DeMeester, T.R., Eads, C.A., Laird, P.W., Ilson, D.H., Kelsen, D.P., Harpole, D., Moore, M.-B., Danenberg, K.D., Danenberg, P.V., Meltzer S.J. Hypermethylated APC promoter DNA in serum and prognosis in esophageal adenocarcinoma patients. J. Natl. Cancer Inst. 2000; 92:1805-1811.

31. Fleisher AS, Esteller M, Tamura G, Rashid A, Stine OC, Yin J, Zou TT, Abraham JM, Kong D, Nishizuka S, James SP, Wilson KT, Herman JG, Meltzer SJ. Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene 2001; 20:329-335.

32. Selaru F, Zou T, Shustova V, Xu Y, Yin J, Mori Y, Sato F, Wang S, Shibata D, Greenwald BD, Krasna MJ, Abraham JM, Meltzer SJ. Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. Oncogene 2002; 21:475-478.

33. Sato F, Harpaz N, Shibata D, Xu Y, Yin J, Mori Y, Zou T-T, Wang S, Desai K, Leytin A, Selaru F, Abraham JM, Meltzer SJ. Hypermethylation of the p14ARF gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res. 2002; 62:1148-1151.

34. Selaru F, Xu Y, Yin J, Zou T, Liu TC, Mori Y, Abraham JM, Sato F, Wang S, Twigg C, Olaru A, Shustova V, Leytin A, Shibata D, Harpaz N, Meltzer SJ. Artificial neural networks distinguish among subtypes of neoplastic colorectal lesions. Gastroenterol. 2002; 122:606-613.

35. Smolinski KN, Abraham JM, Souza RF, Yin J, Wang S, Xu Y, Zou T-T, Kong D, Fleisher AS, Meltzer SJ. A functional promoter for the squamous differentiation marker esophagin that is activated during differentiation of cultured esophageal cells. Genomics 2002; 79:875-880.

36. Xu Y, Selaru FM, Yin J, Zou TT, Shustova V, Mori Y, Sato F, Liu TC, Olaru A, Wang S, Kimos MC, Perry K, Desai K, Greenwald BD, Krasna MJ, Shibata D, Abraham JM, Meltzer SJ. Artificial neural networks and gene filtering distinguish between global gene expression profiles of Barrett's esophagus and esophageal cancer. Cancer Res. 2002; 62:3493-3497.

37. Zou T, Selaru F, Xu Y, Yin J, Shustova V, Mori Y, Sato F, Liu TC, Abraham JM, Meltzer SJ. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 2002; 21:4855-4862.

38. Mori Y, Selaru FM, Olaru A, Perry K, Kimos MC, Tamura G, Matsubara N, Sato F, Wang S, Xu Y, Yin J, Zou T-T, Leggett B, Young J, Nukiwa T, Stine OC, Abraham JM, Shibata D, Meltzer SJ. Instabilotyping reveals novel unique mutational spectra in microsatellite-unstable gastric cancers. Cancer Res. 2002; 62:3641-3645.

39. Shibata DM, Sato F, Mori Y, Perry K, Yin J, Wang S, Xu Y, Olaru A, Selaru F, Spring K, Young J, Abraham JM, Meltzer SJ. Hypermethylation of HPP1 is associated with hMLH1 hypermethylation in gastric adenocarcinomas. Cancer Res. 2002 Oct 15; 62(20):5637-40.

40. Sato F, Shibata D, Harpaz N, Xu Y, Yin J, Mori Y, Wang S, Olaru A, Deacu E, Selaru F, Kimos M, Hytiroglou P, Young J, Leggett B, Gazdar AF, Toyooka S, Abraham JM, Meltzer SJ. Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res. 2002 Dec 1; 62(23):6820-6822.

41. Wang S, Mori Y, Sato F, Yin J, Xu Y, Zou TT, Olaru A, Kimos MC, Perry K, Selaru FM, Deacu E, Sun M, Shi YC, Shibata D, Abraham JM, Greenwald BD, Meltzer SJ. An LOH and mutational investigation of the ST7 gene locus in human esophageal carcinoma. Oncogene 2003 Jan 23; 22(3):467-470.

42. Mori Y, Selaru F, Sato F, Xu Y, Wang S, Yin J, Abraham JM, Olaru A, Deacu E, Kimos M, Perry K, Shibata D, Young J, Leggett B, Meltzer SJ. The impact of microsatellite instability on the molecular phenotype of colorectal tumors. Cancer Res. 2003 Aug 1; 63(15):4577-4582.

43. Olaru A, Mori Y, Yin J, Wang S, Kimos MC, Perry K, Xu Y, Sato F, Selaru FM, Deacu E, Shibata D, Abraham JM, Meltzer SJ. An LOH and mutational analysis of the ACTRII gene locus in human colorectal tumors. Lab. Invest. 2003 Dec; 83(12):1867-1861.

44. Selaru FM, Yin J, Xu Y, Epstein S, Sato F, Mori Y, Olaru A, Deacu E, Wang S, Sterian A, Fulton A, Abraham JM, Shibata D, Baquet C, Stass SA, Meltzer SJ. An unsupervised approach to identify molecular phenotypic components influencing breast cancer features. Cancer Res. 2004 Mar 1; 64(5):1584-1588.

45. Mori Y, Yin J, Sato F, Sterian A, Simms LA, Selaru FM, Xu Y, Olaru A, Wang S, Deacu E, Abraham JM, Young J, Leggett BA, Meltzer SJ. Identification of genes uniquely involved in MSI-H colon carcinogenesis by expression profiling combined with epigenetic scanning. Cancer Res. 2004 Apr 1; 64(7):2434-2438.

46. Schulmann K, Yin J, Sterian A, Xu T, Sato F, Bryant L, Mori Y, Olaru A, Deacu E, Wang S, Brenner DE, Krasna MJ, Abraham JM, Baron JA, Greenwald BD, Meltzer SJ. Methylation profiling for the prediction of Barrett's esophagus progression. Gastroenterol. 2004 Jul; 127(1):331.

47. Kimos MC, Borkowski A, Wang LD, Yang CS, Perry K, Olaru A, Sisodia L, Selaru FM, Mori Y, Xu Y, Yin J, Wang S, Abraham JM, Meltzer SJ. Esophagin and proliferating cell nuclear antigen (PCNA) as biomarkers of human esophageal epithelial differentiation and proliferation in carcinogenesis. Int. J. Cancer 2004 Sep 1; 111(3):415-417.

48. Deacu E, Mori Y, Sato F, Yin J, Olaru A, Sterian A, Xu Y, Wang S, Schulmann K, Bryant L, Kan T, Abraham JM, Meltzer SJ. Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces TGF-beta response pathway genes. Cancer Res. 2004 Nov 1; 64(21):7690-7696.

49. Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y, Olaru A, Wang S, Mori Y, Deacu E, Hamilton J, Kan T, Krasna MJ, Beer DG, Pepe MS, Abraham JM, Feng Z, Schmiegel W, Greenwald BD, Meltzer SJ. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 2005 Jun 9; 24(25):4138-4148.

50. Schulmann K, Mori Y, Croog V, Yin J, Olaru A, Sterian A, Sato F, Wang S, Xu Y, Deacu E, Abraham JM, Schmiegel W, Harpaz N, Meltzer SJ. Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. Gastroenterol. 2005 Jul; 129:74-85.

51. Sato F, Abraham JM, Yin J, Kan T, Ito T, Mori Y, Hamilton JP, Jin Z, Cheng Y, Paun B, Berki AT, Wang S, Shimada T, Meltzer SJ. Polo-like kinase (PLK) and Survivin are Esophageal Tumor-Specific Promoters. Biochem. Biophys. Res. Commun. 2006 Apr 7; 342(2):465-471.

52. Wang S, Zhan M, Yin J, Abraham JM, Mori Y, Sato F, Xu Y, Olaru A, Li H, Schulmann K, Sterian A, Kan T, Hamilton JP, Chai K, Deacu E, Berki AT, Greenwald BD and Meltzer SJ. Transcriptional profiling supports that Barrett's metaplasia is an advanced intermediate stage in esophageal adenocarcinoma. Oncogene 2006 Jun 1; 25(23):3346-3356.

53. Hamilton JP, Sato F, Greenwald BD, Suntharalingam M, Krasna MJ, Edelman MJ, Doyle LA, Berki AT, Abraham JM, Mori Y, Kan T, Mantzur C, Paun T, Wang S, Ito T, Jin Z, Meltzer SJ. Promoter hypermethylation and response to chemotherapy and radiation in esophageal cancer. Clin. Gastroenterol. Hepatol. 2006 Jun; 4(6):701-708.

54. Sterian A, Kan T, Mori Y, Berki A, Olaru A, Schulmann K, Sato F, Wang S, Paun B, Cai K, Hamilton JP, Abraham JM, Greenwald BD, Meltzer SJ. Mutational and deletion analyses of the chromosome 4q24-31 region in esophageal adenocarcinoma. Oncology 2006 Jul 7; 70(3):168-172.

55. Mori Y, Cai K, Cheng Y, Wang S, Paun B, Hamilton JP, Jin Z, Sato F, Berki AT, Kan T, Ito T, Mantzur C, Abraham JM, Meltzer SJ. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and five other genes in colon cancer. Gastroenterol. 2006 Sep; 131(3): 797-808.

56. Hamilton JP, Sato F, Jin Z, Greenwald BD, Ito T, Mori Y, Paun B, Kan T, Cheng Y, Wang S, Mantzur C, Abraham JM, Meltzer SJ. Reprimo methylation is a potential early biomarker of Barrett's-associated neoplastic progression. Clin. Cancer Res. 2006 Nov 15; 12(22):6637-6642.

57.Kan T, Paun B, Mori Y, Sato F, Jin Z, Hamilton JP, Ito T, Cheng Y, David S, Olaru A, Yang J, Agarwal R, Abraham JM, Meltzer SJ. Rarity of somatic mutation and frequency of normal sequence variation detected in sporadic colon adenocarcinoma using high-throughput cDNA sequencing. Bioinformatics & Biology Insights 2007; 1:1-16.

58. Abraham JM, Sato F, Cheng Y, Paun B, Ito T, Kan T, Olaru A, Jin Z, Yang J, Agarwal R, David S, Hamilton JP, Mori Y, Meltzer SJ. A Novel Decapeptide that Binds Avidly and Delivers Radioisotope to Colon Cancer Cells. PLoS ONE 2007 Oct 3;2(10):e964.

59. Jin Z, Olaru A, Yang J, Sato F, Cheng Y, Mori Y, Mantzur C, Paun B, Hamilton JP, Ito T, Kan T, Wang S, David S, Agarwal R, Beer DG, Abraham JM, Meltzer SJ. Hypermethylation of Tachykinin-1 is Associated with a Poor Prognosis in Human Esophageal Squamous Cell Carcinoma. Clin. Cancer Res. 2007 Nov 1;13(21):6293-6300.

60. Jin Z, Mori Y, Hamilton JP, Olaru A, Sato F, Yang J, Ito T, Paun B, Kan T, Agarwal R, Meltzer SJ. Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis. Cancer 2008 Jan 1;112(1):43-49. 147. Jin Z, Hamilton JP, Yang J, Mori Y, Olaru A, Sato F, Ito T, Kan T, Cheng Y, Paun B, David S, Agarwal R, Abraham JM, Meltzer SJ. Hypermethylation of the AKAP12 Promoter is a Potential Biomarker of Barrett's-Associated Esophageal Neoplastic Progression. Cancer Epidemiology, Biomarkers & Prevention 2008 Jan; 17(1):1-16.

61. Selaru FM, Wang S, Yin J, Schulmann K, Xu Y, Yuriko Mori Y, Olaru A, Sato F, Hamilton JP, Abraham JM, Schneider P, Greenwald BD, Brabender J, Meltzer SJ. Beyond Field Effect: Analysis of Shrunken Centroids in Normal Esophageal Epithelia Detects Concomitant Esophageal Adenocarcinoma. Bioinformatics & Biology Insights, 2007; 1:127-136.

62. Ito T, Shimada Y, Kan T, David S, Abraham JM, Mori Y, Agarwal R, Cheng Y, Paun B, Jin Z, Olaru A, Hamilton JP, Yang J, Meltzer SJ, Sato F. PTTG1 promotes lymph node metastasis in esophageal squamous cell carcinoma by increasing cell motility. Cancer Research 2008 May 1;68(9):3214-3224.

63. Sato F, Jin Z, Schulmann K, Wang J, Greenwald BD, Ito T, Kan T, Hamilton JP, Yang J, Paun B, David S, Olaru A, Cheng Y, Mori Y, Abraham JM, Yfantis HG, Wu T, Fredericksen MB, Wang KK, Canto M, Romero Y, Feng Z, Meltzer SJ. Three-tiered risk stratification method to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS ONE 2008 Apr 2; 3(4):e1890.

64. Ito T, Tanaka E, Kadowaki T, Kan T, Higashiyama M, Shiojima S, Tomoda S, Myoumoto A, Akiyama H, Nobumasa H, Matsumoto S, Miyamoto S, Mitsumori M, Sato F, Watanabe G, Itami A, Meltzer SJ, Tsujimoto G, Shimada Y. An ultrasensitive new DNA microarray chip provides gene expression profiles for preoperative esophageal cancer biopsies without RNA amplification. Oncology 2008 May 30, 73(5-6):366-375.

65. Abraham JM, Cheng Y, Hamilton JP, Paun B, Jin Z, Agarwal R, Kan T, David S, Olaru A, Yang J, Ito T, Selaru FM, Mori Y, Meltzer SJ. Generation of small 32P-labeled peptides as a potential approach to colorectal cancer therapy. PLoS ONE 2008 Jun 25; 3(6):e2508.

66. Jin Z, Hamilton JP, Yang J, Mori Y, Olaru A, Sato F, Ito T, Kan T, Cheng Y, Paun B, David S, Agarwal R, Abraham JM, Meltzer SJ. Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int. J. Cancer 2008 Nov 15;123(10):2331-2336.

67. Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, Yang J, Paun B, Jin Z, Agarwal R, Hamilton JP, Abraham JM, Georgiades C, Alvarez H, Vivekanandan P, Maitra A, Torbenson M, Thuluvath PJ, Gores GJ, LaRusso NF, Hruban R, Meltzer SJ. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 2009 Feb 4;49(5):1595-1601.

68. Kan T, Sato F, Ito T, Matsumura N, David S, Cheng Y, Agarwal R, Paun BC, Jin Z, Olaru AV, Selaru FM, Hamilton JP, Yang J, Abraham JM, Mori Y, Meltzer SJ. The miR-25-93-106b polycistron, activated by de novo genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterol. 2009 May;136(5):1689-700.

69. Jin Z, Cheng Y, Zheng Y, Gu J, Sato F, Olaru AV, Paun B, Yang J, Kan T, Ito T, Hamilton JP, Selaru FM, Mori Y, Agarwal R, David S, Abraham JM, Wolfsen H, Shaheen NJ, Wang J, Canto M, Washington K, Romero Y, Wang KK, Feng Z, Sampliner RD, Meltzer SJ. A multi-center, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res. 2009, in press.

Is this you? Edit Profile